Sherlock Company

Sherlock Biosciences is a biotechnology company engineering the future of molecular diagnostics through CRISPR and synthetic biology. The company leverages its proprietary SHERLOCK and INSPECTR platforms to create low-cost, highly accurate, and rapid tests that can be used in various settings, from clinical labs to the home. Their technology allows for the detection of specific genetic sequences in DNA or RNA, providing actionable health information without the need for complex instrumentation. Sherlock's first product was the first CRISPR-based diagnostic to receive FDA Emergency Use Authorization for COVID-19 detection. The company aims to decentralize healthcare by providing "anywhere" testing solutions for infectious diseases, oncology, and consumer health. Through the acquisition of Sense Biodetection, Sherlock has expanded its portfolio to include instrument-free, handheld molecular testing platforms.